1.Valproate Is Contraindicated in POLG1 Mutations.
Pediatric Gastroenterology, Hepatology & Nutrition 2019;22(1):105-106
No abstract available.
Valproic Acid*
2.Study for the hepatotoxicity in mice with long-term administration of valproate.
Journal of the Korean Child Neurology Society 1993;1(1):24-32
No abstract available.
Animals
;
Mice*
;
Valproic Acid*
3.A Case of Valproic Acid Overdose Treated with Continuous Veno-Venous Hemodiafiltration: A Case Report.
Sang Cheon CHOI ; Jung Hwan AHN ; Yoon Seok JUNG ; Young Gi MIN
The Korean Journal of Critical Care Medicine 2009;24(2):99-101
Valproic acid intoxication is a fairly common clinical problem that can result in serious complications. Traditionally the treatment of valproic acid overdose has been limited to supportive measures, but high blood levels may require extracorporeal removal, and publications on this experience are scarce. This case demonstrated continuous veno-venous hemodiafiltration successfully used in patient with severe valproic acid overdose who was hemodynamically unstable.
Hemodiafiltration
;
Humans
;
Valproic Acid
4.Curly Hair Induced by Valproate in Bipolar Disorder.
Clinical Psychopharmacology and Neuroscience 2016;14(1):114-114
No abstract available.
Bipolar Disorder*
;
Hair*
;
Valproic Acid*
5.Erythema Nodosum Associated with Valproate.
Yu Ri WOO ; Dae Won KOO ; Kyung Eun JUNG ; Joong Sun LEE
Annals of Dermatology 2015;27(6):765-766
No abstract available.
Erythema Nodosum*
;
Erythema*
;
Valproic Acid*
6.Valproate Induced Hair Loss and Curly Hair in Bipolar Disorder
Omer Faruk UYGUR ; Hilal UYGUR
Clinical Psychopharmacology and Neuroscience 2019;17(4):566-567
No abstract available.
Bipolar Disorder
;
Hair
;
Valproic Acid
7.L-carnitine vs Extracorporeal Elimination for Acute Valproic acid Intoxication: A Systematic Review.
Byung Keun YANG ; Jae Eun KU ; Young Seon JOO ; Je Sung YOU ; Sung Phil CHUNG ; Hahn Shick LEE
Journal of The Korean Society of Clinical Toxicology 2014;12(2):39-45
PURPOSE: The purpose of this study is to review the evidence comparing the efficacy and safety between L-carnitine and extracorporeal elimination therapy in the management of acute valproic acid L-carnitine vs Extracorporeal Elimination for Acute Valproic acid Intoxication METHODS: PubMed, Embase, Cochrane library, Web of Science, KoreaMed, KMbase, and KISS were searched, using the terms carnitine and valproic acid. All studies, regardless of design, reporting efficacy or safety endpoints were included. Reference citations from identified publications were reviewed. Both English and Korean languages were included. Two authors extracted primary data elements including poisoning severity, presenting features, clinical management, and outcomes. RESULTS: Thirty two articles including 33 cases were identified. Poisoning severity was classified as 3 mild, 11 moderate, and 19 severe cases. Nine cases were treated with L-carnitine while 24 cases received extracorporeal therapy without L-carnitine. All patients except one expired patient treated with hemodialysis recovered clinically and no adverse effects were noted. A case report comparing two patients who ingested the same amount of valproic acid showed increased ICU stay (3 vs 11 days) in case of delayed extracorporeal therapy. CONCLUSION: Published evidence comparing L-carnitine with extracorporeal therapy is limited. Based on the available evidence, it is reasonable to consider L-carnitine for patients with acute valproic acid overdose. In case of severe poisoning, extracorporeal therapy would also be considered in the early phase of treatment.
Carnitine*
;
Humans
;
Poisoning
;
Renal Dialysis
;
Valproic Acid*
8.A Study of Serum Carnitine Levels in Epileptic Children with Antiepileptic Drugs.
Young Min YOON ; Joo Taek LEE ; Eun Sook SUH ; Chang Hwi KIM
Journal of the Korean Child Neurology Society 1999;6(2):277-284
PURPOSE: Epileptic patients under prolonged treatment with anticonvulsants such as valproate tend to have low serum carnitine level. The object of this study is to observe the interrelationship between anticonvulsants and serum carnitine level and its related symptoms. METHODS: We measured the serum carnitine levels in 31 epileptic patients (18 males, 13 females) receiving diverse antiepileptic drugs and 32 healthy children (20 males, 12 females) using enzymatic cycling method. RESULTS: 1) Among the control group, total, free, and acyl-carnitine in serum were 50.04+/-11.44, 37.42+/-11.13, and 13.98+/-7.49micro mol/L (mean+/-S.D.), respectively, and no significant differences were observed between age and sex. 2) Among 31 patients with treatment, total serum carnitine level and free carnitine level below 2 standard deviation from the mean control value was not observed. 3) Among 31 patients with treatment, total serum carnitine level below 2 standard deviation from the age matched mean control value was not observed. 4) No significant relationship was observed between the serum carnitine level and the dosage, duration and the serum concentration of the antiepileptic drugs. 5) There were no abnormalities in serum AST, ALT levels among the patients treated. CONCLUSION: Although our study didn't reveal that serum carnitine level can be lowered in patients treated with anticonvulsants such as valproate, many others reported it. So periodic measurement of serum carnitine level before and after treatment with anticonvulsants should be considered.
Anticonvulsants*
;
Carnitine*
;
Child*
;
Humans
;
Male
;
Valproic Acid
9.Comparative Add-on Trial of Vigabatrin and Valproic Acid on Intractable Partial Seizures with Carbamazepine Monotherapy.
Sang Kun LEE ; Hyun Woo NAM ; In Jin CHANG
Journal of the Korean Neurological Association 1997;15(4):754-761
PURPOSE: To evaluate the efficacy of vigabatrin and valproic acid add-on therapy in the treatment of uncontrolled partial-onset seizures through randomized active controlled parallel-group trial. METHODS: Criteria for entry included a requirement for three or more partial seizures per month despite the blood level of carbamazepine was within therapeutic range. During the 56-day baseline period, patients had at least 6 partial onset seizures. Vigabatrin or valproic acid were administered as the second drug in a randomized fashion. RESULTS: Forty one patients completed the trial(21 for vigabatrin, 20 for valproic acid). There is no statistically significant difference in age, age at onset, baseline seizure frequency, dose of carbamazepine, and serum level of carbamazepine between two groups. Two patients of vigabatrin-treated group and three patients of valproic acid treated group were dropped out because of side effects. The mean vigabatrin and valproic acid does were 2809 and 1490 mg, respectively. The percentage of patients achieving at least a 50% reduction in seizure frequency at the end of 8-week of add-on trial was 62% among vigabatrin-treated patients and was 50% for patients who received valproic acid(not statistically different). There was no significant difference in seizure reduction, percent seizure reduction, and truncated percent seizure reduction between two groups. The side effects were mild and transient neurotoxic symptoms in the patients who completed the trial(5 patients for vigabatrin, 10 patients for valproic acid). CONCLUSIONS: This trial indicates that vigabatrin and valproic acid are safe and effective in the treatment of intractable partial-onset seizures. The efficacy of vigabatrin as a new add-on antiepileptic drug is comparable to the previous valproic acid carbamazepine combination in the sense of seizure reduction and maybe even superior to that in the consideration of side effects
Carbamazepine*
;
Humans
;
Seizures*
;
Valproic Acid*
;
Vigabatrin*
10.A Case of Ultra-rapid Cycling Bipolar Disorder Recovered by Lamotrigine Combination.
Young Sup WOO ; Jeong Ho CHAE ; Tae Youn JUN ; Won Myong BAHK
Korean Journal of Psychopharmacology 2006;17(2):229-232
The anticonvulsant lamotrigine has been reported to be efficacious and well tolerated in treatment of bipolar patients. Recently, its efficacy in rapid cycling states has attracted interest, however there was no reports about lamotrigine in treatment of ultra-rapid cycling bipolar disorder. Here we present the case of a male patient with bipolar disorder who developed an ultra-rapid cycling state. The addition of lamotrigine to prior valproate treatment succeeded to improve the ultra-rapid cycling.
Bipolar Disorder*
;
Humans
;
Male
;
Valproic Acid